Per National Comprehensive Cancer Network guidelines (www.nccn.org), variants in ATM confer an absolute risk of 15–40% for breast cancer, 5–10% for pancreatic cancer, and <3% for ovarian cancer. The gene discussed is ATM; the disease is breast carcinoma.